MAVERIC-2 trial will evaluate the impact of CardiolRx(TM) following cessation of interleukin-1 blocker therapy (rilonacept or anakinra) and is expected to run concurrently with the Company's planned ...
Treatment with goflikicept, an anti-cytokine biologic, allows patients to discontinue other therapies for idiopathic recurrent pericarditis (IRP) and reduces the risk for recurrence compared with ...
Myocarditis and pericarditis are conditions that involve heart inflammation. Myocarditis affects the heart muscle itself, while pericarditis impacts the pericardium — the layer of tissue that ...
Designed to assess the impact of CardiolRx™ on preventing episodes of recurrent pericarditis, the first patient has been randomized by Northwestern University in Chicago. Based on a successful ...
Pericardial disease are conditions that affect your pericardium. Your pericardium is a flexible, two-layered sac that surrounds your heart. Your pericardium contains your heart in your chest wall. It ...
In a preclinical model of acute pericarditis, cannabidiol was found to significantly reduce pericardial effusion and thickening. The Food and Drug Administration (FDA) has granted Orphan Drug ...
Detailed price information for Cardiol Therapeutics Inc (CRDL-T) from The Globe and Mail including charting and trades.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback